- Home
- JTAI vs HOOK Comparison
JTAI vs HOOK Comparison
Compare JTAI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- HOOK
- Stock Information
- Founded
- JTAI 2018
- HOOK 2011
- Country
- JTAI United States
- HOOK United States
- Employees
- JTAI N/A
- HOOK N/A
- Industry
- JTAI Blank Checks
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- HOOK Health Care
- Exchange
- JTAI Nasdaq
- HOOK Nasdaq
- Market Cap
- JTAI 9.9M
- HOOK 9.3M
- IPO Year
- JTAI N/A
- HOOK 2019
- Fundamental
- Price
- JTAI $4.21
- HOOK $1.56
- Analyst Decision
- JTAI
- HOOK Buy
- Analyst Count
- JTAI 0
- HOOK 4
- Target Price
- JTAI N/A
- HOOK $10.67
- AVG Volume (30 Days)
- JTAI 429.0K
- HOOK 166.8K
- Earning Date
- JTAI 05-15-2025
- HOOK 06-17-2025
- Dividend Yield
- JTAI N/A
- HOOK N/A
- EPS Growth
- JTAI N/A
- HOOK N/A
- EPS
- JTAI N/A
- HOOK N/A
- Revenue
- JTAI $13,648,668.00
- HOOK $9,351,000.00
- Revenue This Year
- JTAI $13.37
- HOOK N/A
- Revenue Next Year
- JTAI $201.13
- HOOK N/A
- P/E Ratio
- JTAI N/A
- HOOK N/A
- Revenue Growth
- JTAI N/A
- HOOK N/A
- 52 Week Low
- JTAI $2.30
- HOOK $0.72
- 52 Week High
- JTAI $166.50
- HOOK $8.50
- Technical
- Relative Strength Index (RSI)
- JTAI 52.14
- HOOK 56.94
- Support Level
- JTAI $3.85
- HOOK $1.51
- Resistance Level
- JTAI $4.70
- HOOK $1.65
- Average True Range (ATR)
- JTAI 0.30
- HOOK 0.14
- MACD
- JTAI 0.04
- HOOK -0.02
- Stochastic Oscillator
- JTAI 53.77
- HOOK 34.37
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.